Gene or Genome
Gilead Expands Access to Long-Acting HIV PrEP with Licensing Deals for Generic Lenacapavir
Gilead Sciences, lenacapavir, HIV PrEP, generic licensing, long-acting HIV prevention, global health access
Shattuck Labs Shifts Focus to IBD Drug, Discontinues CD47 Program and Reduces Workforce by 40%
Shattuck Labs, CD47 program, workforce reduction, IBD drug, SL-325, DR3 antagonist antibody
Aktis Oncology Secures $175M Series B Funding with Backing from Industry Giants
Aktis Oncology, Series B funding, targeted alpha radiopharmaceuticals, cancer treatment, pharmaceutical industry, investment, Lilly, BMY, MRK.
Cereno’s CS1 Shows Promising Results in Reducing PAH Risks in Phase 2 Trial
Cereno Scientific, CS1, HDAC inhibitor, Pulmonary Arterial Hypertension (PAH), Phase 2 trial, Epigenetic modulation, CardioMEMS HF System, Disease-modifying treatment
FDA Considers Restricting PD-1 Drugs in Stomach and Esophageal Cancers Based on PD-L1 Expression
PD-1 drugs, stomach cancer, esophageal cancer, PD-L1 expression, FDA restrictions, pembrolizumab, nivolumab, tislelizumab
FDA Advisory Panel Rejects PD-1 Inhibitors for Gastric and Esophageal Cancers with Low PD-L1 Expression
FDA, PD-1 inhibitors, gastric cancer, esophageal cancer, PD-L1 expression, biomarker, oncology, drug approval
UCB Expands Bimzelx Indications with Three New FDA Approvals for Chronic Inflammatory Diseases
Bimzelx, UCB, FDA approvals, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, IL-17A, IL-17F inhibitor
Aptadir Therapeutics Unveils Novel RNA Inhibitors to Combat Cancer and Genetic Disorders
Aptadir Therapeutics, RNA inhibitors, DNMT1 interacting RNAs (DiRs), Cancer treatment, Genetic diseases, Epigenetic targeting, RNA therapeutics
Ascendis Challenges BioMarin’s Dominance with Promising Achondroplasia Drug Data
Achondroplasia, Ascendis Pharma, BioMarin, TransCon CNP, VOXZOGO, Dwarfism Treatment
Incyte’s PD-1 Drug Zynyz: A Strategic Pipeline Component Despite Recent Trial Success
Incyte, Zynyz, PD-1 inhibitor, anal cancer, pipeline strategy, clinical trials, FDA approval